Icosavax

Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. It focuses on developing vaccine candidates for viral causes of pneumonia in older adults. The company was founded by Neil King and David Baker on November 1, 2017 and is headquartered in Seattle, WA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.

– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) -

Icosavax Reports Second Quarter 2022 Financial Results and Provides Corporate Update

- Antigen component of IVX-411 found to be unstable; issue specific to molecule, with no evidence of read-through to other Icosavax programs -

Icosavax Announces Results from IVX-411 Drug Product Investigation and Outlines Additional Corporate Milestones

SEATTLE, July 06, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in the William Blair Biotech Focus Conference taking place from July 12-13, 2022, in New York.

Icosavax to Participate in the William Blair Biotech Focus Conference

- IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older adult groups -

Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV

SEATTLE, June 01, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop combination vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in the Jefferies Healthcare Conference taking place from June 8-10, 2022.

Icosavax to Participate in the Jefferies Healthcare Conference

- Enrollment completed in older adults portion of Phase 1/1b trial of IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen -

Icosavax Reports First Quarter 2022 Financial Results and Provides Corporate Update

The company's Q4 update made investors feel a little better after receiving disappointing news last week.

Why Icosavax Stock Is Soaring Today

- Completed dosing in older adults portion of Phase 1/1b clinical trial for IVX-121, a VLP vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen -

Icosavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Seattle-based vaccine company Icosavax posted disappointing clinical data today for its experimental COVID-19 vaccine, sending its stock into a dive.

Icosavax posts COVID-19 vaccine data ‘below our expectations' as shares plummet

Icosavax Inc (NASDAQ: ICVX) has announced topline interim results from its ongoing Phase 1/2 trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD). In the naïve setting, adjuvant effect on immunogenicity and a dose-response were.

Why Icosavax's Shares Are Trading Lower Today

- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company's platform and VLP technology; end-to-end drug product investigation underway -

Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2

SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced that the company will participate in the Cowen 42nd Annual Health Care Conference taking place virtually from March 7-9, 2022.

Icosavax to Participate in the Cowen 42nd Annual Health Care Conference

SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today provided a corporate update and shared anticipated milestones for 2022.

Icosavax Provides Corporate Update and Anticipated Milestones for 2022

- Dr. Shiver has contributed to the licensure of 14 pharmaceutical addressing global infectious diseases - - Dr. Shiver has contributed to the licensure of 14 pharmaceutical addressing global infectious diseases -

Icosavax Appoints Dr. John Shiver to Board of Directors

- Initiated a Phase 1/1b clinical trial for IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen -

Icosavax Reports Third Quarter 2021 Financial Results and Provides Corporate Update

SEATTLE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced that Adam Simpson, Chief Executive Officer of Icosavax, will participate in two upcoming investor conferences.

Icosavax to Participate in Upcoming Investor Conferences

We are now in the “digital era” of vaccine development, University of Washington researcher Neil King said at the GeekWire Summit in Seattle on Tuesday.

Icosavax co-founder and UW researcher Neil King talks vaccine development in the ‘digital era'

- Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain -

Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update

SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of Elizabeth Bekiroğlu to General Counsel.

Icosavax Appoints Elizabeth Bekiroğlu to General Counsel

Couchbase

Robinhood

MENLO PARK, Calif.--(BUSINESS WIRE)--Adams Street Partners, a private markets investment firm with $45 billion in assets under management, announced today that within a 7-day period last week three companies within its Growth Equity portfolio launched initial public offerings (IPOs). This string of public offerings includes the IPOs of Couchbase (NYSE: BASE) on July 22, Icosavax (NYSE: ICVX) on July 28, and Robinhood (NYSE: HOOD) on July 29. “Congratulations to the teams at Robinhood, Couchbase

Adams Street Partners Growth Equity Strategy Participates in Three High-Profile Public Offerings In Seven Days

SEATTLE, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced the closing of its initial public offering of 13,953,332 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,819,999 additional shares, at an initial public offering price of $15.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Icosavax, were $209.3 million. Icosavax's common stock is listed on the Nasdaq Global Select Market under the ticker symbol “ICVX.”

Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Traeger

Nuvalent

Riskified Ltd

Making their market debuts were three biotechs, a fintech, and a grill maker. Shares of one biotech, Icosavax, rocketed 214%.

5 Companies Join Robinhood in Going Public

Icosavax is having quite the debut as Washington state's newest public company.

Icosavax stock skyrockets 200% on first day of trading for newly public Seattle biotech company

SEATTLE--(BUSINESS WIRE)--Icosavax Announces Pricing of Upsized Initial Public Offering

News for Icosavax Stock (ICVX)